Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

Original languageEnglish
Pages (from-to)19-27
Number of pages9
JournalJournal of Neuroimmunology
Early online date7 Nov 2018
Publication statusPublished - 15 Jan 2019


  • Anti-drug antibodies
  • Bridging ELISA
  • Interferon-beta
  • Luciferase-based bioassay
  • Multiple sclerosis
  • Neutralizing antibodies


Dive into the research topics of 'Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study'. Together they form a unique fingerprint.

Cite this